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S U M M A R Y
Objective: To compare the spectrum of infection, comorbidities, outcomes, and mortality of patients
admitted to the intensive care unit (ICU) due to community-acquired or healthcare-associated severe
sepsis.
Methods: This prospective cohort study was conducted in three university medical centers in Lebanon
from February 2005 to December 2006. Patients with severe sepsis were included and followed up until
hospital discharge or death.
Results: One hundred and twenty patients were included of whom 60% had community-acquired
infections (CAI) and 40% had healthcare-associated infections (HAI). The most common infection in both
groups was pneumonia. Hematologic malignancies were the only comorbidity more prevalent in HAI
than in CAI (p = 0.047). Fungal infections and extended-spectrum beta-lactamase (ESBL) organisms were
more frequent in HAI than in CAI (p = 0.04 and 0.029, respectively). APACHE and SOFA scores were high
and did not differ between the two groups, nor did the proportion of septic shock, while mortality was
signiﬁcantly higher in the HAI patients than in the CAI patients (p = 0.004). On multivariate analysis for
mortality, independent risk factors were the source of infection acquisition (p = 0.004), APACHE II score
(p = 0.006), multidrug-resistant Pseudomonas infections (p = 0.043), and fungal infections (p = 0.006).
Conclusions: Severe sepsis and septic shock had a high mortality rate, especially in the HAI group.
Patients with risk factors for increased mortality should be monitored and aggressive treatment should
be administered.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Patients with severe sepsis admitted to the intensive care unit
(ICU) require costly and time-consuming treatment, but have a
high mortality rate, ranging from 30% to 50%.1 Important
contributors to this increased mortality risk include the underlying
disease, comorbidities, type of infection, and microbiology.
Previous studies addressing these infections in the ICU have
focused on prevalence, the means to improve outcomes, and early* Corresponding author. Tel.: +9611615300x9314; fax: +9611615295.
E-mail address: georges.dabar@usj.edu.lb (G. Dabar).
http://dx.doi.org/10.1016/j.ijid.2015.05.024
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).goal-directed therapy.2–5 Comparative data on the outcomes of
patients with community-acquired infections (CAI) and health-
care-associated infections (HAI) requiring ICU care for severe
sepsis are scarce.6 It is unclear whether potential differences in
outcomes between these two types of infection are due to
differences in population characteristics (e.g., age, comorbidities)
and/or to heterogeneity in disease traits (e.g., causative micro-
organisms, microbial resistance, and severity of the host inﬂam-
matory response). To help address this knowledge gap, a cohort
study of patients with severe sepsis admitted to the ICU was
performed, with a focus on comparing characteristics, disease
severity, and outcomes of community- vs. healthcare-associated
infections.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Setting and patient selection
A prospective multicenter cohort study of critically ill patients
admitted to the medical or surgical ICU at one of three tertiary
teaching hospitals in Beirut, Lebanon was conducted (Saint Joseph
University Faculty of Medicine, American University Hospital of
Beirut, and Balamand University Faculty of Medicine and Medical
Sciences). These were closed ICUs that were run by a team of
critical care specialists assisted by physicians-in-training. Adults
aged 18 years or older diagnosed with severe sepsis either at
admission to the ICU or occurring during the ICU stay were
included in the cohort, and followed until hospital discharge or
death. The ethics committees at the three participating sites
approved the study protocol and waived the need for patient
informed consent due to the absence of interaction with patients.
2.2. Deﬁnitions
Sepsis was deﬁned as a suspected or conﬁrmed infection and
the presence of at least two systemic inﬂammatory response
syndrome criteria: fever or hypothermia, tachycardia, tachypnea,
and altered leukocyte count.7 Severe sepsis was deﬁned as sepsis
and the presence of at least one sepsis severity criterion (i.e.,
evidence of organ dysfunction such as hypotension or hypoperfu-
sion).4 Septic shock, a subset of severe sepsis, was deﬁned as
sepsis-induced hypotension (systolic blood pressure 90 mmHg
or a reduction of 40 mmHg from baseline) despite adequate ﬂuid
resuscitation and the presence of perfusion abnormalities such as
lactic acidosis, oliguria, and altered mental status.8,9
Critically ill patients were considered ‘medical’ if admitted to
the ICU for a medical problem, and ‘surgical’ if admitted following
scheduled or unscheduled surgery. ICU criteria for admission were
according to each unit’s speciﬁc protocol.
Infection was identiﬁed based on clinical history, physical
examination, laboratory and microbiological data, and the
administration of antibiotics (excluding antimicrobial prophylax-
is) according to the International Sepsis Forum Consensus
Conference.6 Categorization of infection as clinically documented
was assessed on a daily basis by the treating physician along with a
consultant infectious disease specialist; a diagnosis of microbio-
logically documented infection was based on the same clinical
information complemented by microbiology data such as cultures
of blood or body ﬂuid from a suspected site of infection.6 Any
organism found in clinical cultures can cause infection or
colonization; the latter is deﬁned by positive cultures without
signs and symptoms related to an infectious syndrome. This
situation can be transient where some microbes are ﬁnally
eradicated by the host immune response, while others can later
promote symptomatic infections when they gain access to usually
sterile body sites, e.g., the bloodstream. Investigating clinical
circumstances surrounding positive cultures helped in the
differentiation between infection and colonization.10
In accordance with the criteria of the Centers for Disease
Control and Prevention,11 an infection developing >48 h after
hospital admission or within 30 days after hospital discharge was
deﬁned as healthcare-associated. An infection present on admis-
sion to the hospital or developing within 48 h or less from the time
of admission was deﬁned as community-acquired.
Gram-negative bacteria were considered to be extended-
spectrum beta-lactamase (ESBL)-producing pathogens if they
belonged to the Enterobacteriaceae family and were resistant to
more than one third-generation cephalosporin or aztreonam.
Multidrug-resistant Pseudomonas species were deﬁned based
on resistance to at least three of the following antibiotics:Pseudomonas acting beta-lactams, carbapenems, aminoglyco-
sides, and quinolones.12 The consideration of fungal infection
was challenging. Isolation in cultures or identiﬁcation techniques
is not a surrogate for infection and the clinical status of the patient
often prevented biopsy sampling. Consequently, the diagnosis of
fungal infection required early recognition of clinical and
radiological signs and interpretation of microbiological results in
context.13
2.3. Data collection
At the time of admission to the ICU, data collection included
demographic characteristics (age, sex), the presence of comorbid
conditions (liver cirrhosis, cancer (metastatic and non-metastatic),
severe chronic obstructive pulmonary disease, bone marrow
transplantation, hematological malignancy, diabetes mellitus,
heart failure, and chronic renal failure requiring renal replacement
therapy), and the presence and site of infection (if known). In
addition, the severity of the acute illness and organ dysfunction at
the time of ICU admission was assessed using the Acute Physiology
and Chronic Health Evaluation (APACHE) II score and the
Sequential Organ Failure Assessment (SOFA) score. ICU and
hospital length of stay and ICU and hospital all-cause mortality
were also recorded.
2.4. Statistical analyses
Continuous variables are reported as the mean with standard
deviation. Categorical variables are reported as the count with
percentage. Comparisons between groups were made with the
Kruskall–Wallis test and the Student t-test or Wilcoxon test for
continuous variables, and with the Chi-square test or Fisher’s exact
test for categorical variables.
Stepwise backward multivariable logistic regression analyses
were performed to examine whether the location of infection
acquisition (HAI vs. CAI), as the main variable of interest, was
associated with in-hospital mortality. Due to the small sample size,
a parsimonious regression model was used, which included for
covariates, sex, APACHE II score (which encompasses age and
comorbid conditions), septic shock, multidrug-resistant Pseudo-
monas infection, and fungal infection. The Hosmer–Lemeshow test
was used to assess goodness-of-ﬁt for the logistic regression
models.
All statistical analyses were performed using SPSS software
version 13 (SPSS Inc., Chicago, IL, USA). Differences were
considered statistically signiﬁcant at a p-value of less than 0.05.
3. Results
3.1. Characteristics of the cohort
Between February 2005 and December 2006, a total of
1464 critically ill patients were admitted to the ICU, of whom
120 with severe sepsis fulﬁlled the eligibility criteria. The
characteristics of the cohort are summarized in Table 1, stratiﬁed
according to whether the infection was community- or hospital-
acquired. Fifty-four percent were men, mean age was 65 years, and
at the time of ICU admission, the mean APACHE II score was 21 and
SOFA score 8. Seventy-eight percent of patients suffered from
septic shock. Patient characteristics did not differ signiﬁcantly
between the two groups with the exception of a higher prevalence
of hematologic malignancies among patients with HAI compared
to CAI (22.9% vs. 9.7%; p = 0.047).
Infectious characteristics of the cohort are displayed in
Table 2. Sixty percent of patients had microbiologically docu-
mented infections, which was almost the same in the two groups.
Table 1
Characteristics and outcomes of the cohort stratiﬁed by community- versus hospital-acquired infection (N = 120)
Variable All (N = 120) Community-acquired
Infection (n = 72)
Hospital-acquired infection (n = 48) p-Value
Demographic characteristics
Male, n (%) 65 (54.6) 37 (51.4) 28 (59.6) 0.38
Age, years, mean (SD) 65.0 (17.7) 65.7 (17.5) 64.6 (18.1) 0.73
Comorbid conditions, n (%)
Alcohol abuse 1 (0.8) 0 1 (2.1) 0.40
Diabetes mellitus 22 (18.3) 14 (19.4) 8 (16.7) 0.70
COPD 15 (12.5) 10 (13.9) 5 (10.4) 0.57
Chronic heart failure 11 (9.2) 6 (8.3) 5 (10.4) 0.75
Chronic renal failure 17 (14.2) 9 (12.5) 8 (16.7) 0.52
Cirrhosis 6 (5.0) 5 (6.9) 1 (2.1) 0.40
Bone marrow transplantation 3 (2.5) 1 (1.4) 2 (4.2) 0.56
Non-metastatic cancer 9 (7.5) 7 (9.7) 2 (4.2) 0.31
Metastatic cancer 17 (14.2) 13 (18.1) 4 (8.3) 0.14
Hematological malignancies 18 (15) 7 (9.7) 11 (22.9) 0.05
Acute severity of illness
APACHE II score, mean (SD) 23.3 (7.8) 22.8 (6.9) 24.1 (8.9) 0.41
SOFA score, mean (SD) 7.9 (3.7) 7.1 (3.0) 8.9 (4.2) 0.02
Septic shock, n (%) 81 (78.0) 57 (79.2) 34 (70.8) 0.30
Hospital outcomes
ICU length of stay, days, mean (SD) 13.4 (26.4) 10.6 (8.4) 17.6 (40.3) 0.152
Hospital LOS, days, mean (SD) 26.8 (21.1) 24.6 (21.6) 30.2 (20.0) 0.156
ICU mortality rate, n (%) 38 (31.7) 17 (23.6) 21 (43.8) 0.02
Hospital mortality rate, n (%) 58 (48.3) 27 (37.5) 31 (64.6) 0.004
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; LOS, length of stay; SD, standard deviation;
SOFA, Sequential Organ Failure Assessment.
Table 2
Characteristics of the infections in the cohort (N = 120)
Infection-related variable All (N = 120) Community-acquired infection (n = 72) Hospital-acquired infection (n = 48) p-Value
Infection category, n (%) 0.71
Clinically suspected 50 (41.2) 31 (43.1) 19 (39.6)
Microbiologically conﬁrmed 70 (58.3) 41 (56.9) 29 (60.4)
Site of infection, n (%)
Respiratory tract 88 (73.3) 50 (69.4) 38 (79.2) 0.24
Urinary tract 55 (45.9) 37 (51.4) 18 (37.5) 0.14
Gastrointestinal tract 26 (21.7) 17 (23.6) 9 (18.8) 0.53
Bacteremia 39 (32.5) 22 (30.6) 17 (35.4) 0.58
Bone and joint 1 (0.8) 0 (0) 1 (2.1) 0.40
CNS 6 (5.0) 5 (6.9) 1 (2.1) 0.23
Skin and soft tissue 10 (8.3) 5 (6.9) 5 (10.4) 0.52
Other 2 (1.7) 0 (0) 2 (4.2) 0.16
Microbial infection type, n (%)
Gram-positive bacterial 30 (25.0) 18 (25.0) 12 (25.0) 1.00
Gram-negative bacterial 59 (49.2) 34 (47.2) 25 (52.1) 0.60
Fungal 24 (20.0) 10 (13.9) 14 (29.2) 0.04
Microbial resistance pattern, n (%)
Enterobacteriaceae ESBL 20 (16.7) 7 (12.5) 13 (30.2) 0.03
MRSA 11 (9.2) 5 (8.9) 6 (14.0) 0.53
MDR Pseudomonas species 11 (9.2) 5 (8.9) 6 (14.0) 0.53
CNS, central nervous system; ESBL, extended-spectrum beta-lactamase; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus.
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two groups and respiratory tract infections represented the most
common infection. The microbial distribution of both CAI and HAI
is displayed in Figure 1. Gram-negative bacteria were the most
commonly encountered pathogens in the two groups (Table 2,
Figure 1), but ESBL-producing Enterobacteriaceae were more
common in patients with HAI compared to those with CAI
(30.2% vs. 12.5%; p = 0.029), and fungal infections were also more
prevalent in patients with HAI compared to CAI (29.2% vs. 13.9%,
p = 0.04).
The ICU and hospital length of stay were not signiﬁcantly
different between the two groups.
3.2. Outcome analyses
A total of 58 (48.3%) patients died in the hospital. The
in-hospital mortality rate was signiﬁcantly higher in patients
with HAI compared to those with CAI (64.6% vs. 37.5%; p = 0.004).The results of the multivariable regression analyses are
summarized in Table 3. The source of infection acquisition (HAI
vs. CAI), which was the main predictor variable, was independently
associated with increased all-cause mortality. Other factors
signiﬁcantly predictive of in-hospital mortality were the APACHE
II score and multidrug-resistant pseudomonal and fungal infec-
tions (Table 3). The Hosmer–Lemeshow test was not signiﬁcant
(p = 0.37), suggesting goodness-of-ﬁt for the models.
4. Discussion
Current deﬁnitions of severe sepsis are restricted to patients
with documented infection.9,14 It was decided to include all
patients with clinically suspected severe sepsis, as in real life, such
patients are treated similarly and/or included in sepsis therapy
trials. In our population, microbial isolates from sterile sites were
obtained in 60% of patients prior to empirical antibiotic therapy,
which is in line with other studies.15–17 The distribution of CAI and
Figure 1. Microbial distribution of nosocomial and community acquired infections. PSA = Pseudomonas aeruginosa; spp = species; H. inﬂuenzae = Haemophilus inﬂuenzae;
candida other = other Candida species.
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60% and 40%, and both groups shared similar features.17
The distribution of all infection sites did not differ signiﬁcantly
between the groups and respiratory infections were the most
common cause of admission. In the present series, 37% of patients
with HAI had a urinary tract infection (UTI), and a higher
percentage was observed in the CAI group (51.4%), while others
have reported rates of 7.2% to 32%.17–20 This high proportion of
UTIs, may be explained by genetics (high prevalence of urinary
lithiasis), environmental factors, and a high rate of community-
acquired resistant bacteria associated with the unrestricted usage
of antibiotics in the community.21
As described in a large body of literature,17,22 Gram-negative
bacilli predominated (49% of reported isolates). The distribution of
Gram-negative and Gram-positive pathogens was similar in thetwo groups. The HAI group had a statistically higher incidence of
fungal infection (29% vs. 14%), probably due to a higher use of
invasive interventions or procedures, total parenteral nutrition, or
other known risk factors for Candida infection.23 The microbiolog-
ical distribution was, however, different from that reported in
other studies where Gram-positive cocci predominated overall15
and fungi were similar in both categories.6,17 This difference is
likely due to country variability affecting the patients’ microbial
proﬁle on inclusion. This latter ﬁnding was emphasized by Martin,
who recognized that causative organisms of sepsis have evolved
over many years.24 A high proportion of our patients had ESBL
pathogens (16%) – the most common resistance pattern. This is one
of the highest ESBL incidences described in the literature.25 The
ESBL pattern occurred more frequently in the HAI group than in the
CAI group (p = 0.029). Many studies have examined the clinical
Table 3
Univariate and multivariable analyses examining factors associated with all-cause hospital mortality
Predictor variable Univariate analysis Multivariable analysisa
Unadjusted OR 95% CI p-Value Adjusted OR 95% CI p-Value
Demographic characteristics
Men (vs. women) 1.70 0.82–3.52 0.589 2.67 0.91–7.81 0.074
Acute severity of illness
APACHE II score (per 1-unit increase) 1.09 1.04–1.16 0.001 1.10 1.02–1.19 0.020
Septic shock (vs. none) 5.11 1.90–13.75 0.001 2.96 0.71–12.29 0.135
Infection-related variables
Hospital-acquired (vs. community-acquired) 3.04 1.42–6.50 0.004 3.26 1.13–9.39 0.028
MDR Pseudomonas aeruginosa (vs. non-MDR) 5.92 1.21–29.01 0.028 7.05 1.07–46.62 0.043
Fungal infection (vs. other) 4.20 1.53–11.52 0.005 5.71 1.64–19.91 0.006
APACHE, Acute Physiology and Chronic Health Evaluation; CI, conﬁdence interval; OR, odds ratio; MDR, multidrug-resistant.
a Hosmer–Lemeshow goodness-of-ﬁt test, p = 0.366.
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an increase in mortality caused by these resistant microorgan-
isms.25,26 The occurrence of multidrug-resistant P. aeruginosa,
recently proven to be an independent factor of 30-day mortality,27
was similar in the two groups studied. This similarity may be due
to the low number of patients in both groups.
With regard to comorbidities, the patients in the HAI group
showed a higher rate of hematologic malignancies than those in
the CAI group, concordant with earlier studies.6,17 The severity of
illness assessed by the APACHE II and SOFA scores was also
comparable in the two groups, consistent with prior studies.6
In the present study, the overall hospital mortality rate was
48%; although high, similar rates have been reported in non-
European/North American studies.16,28 It is, of course, difﬁcult to
compare the epidemiology and outcomes of severe sepsis in
different settings due to different populations or methodologies. In
fact, some studies have differentiated between early (<3 days) and
late mortality,14 while others have separated mortality related to
severe sepsis from that due to septic shock.17 Moreover a lack of
bed availability may account for the higher mortality of septic
patients admitted to the ICU.29 In the setting of the present study,
because of limited ICU beds, patients with severe sepsis are triaged
to medical or surgical wards, while patients transferred to the ICU
have a higher severity of illness (e.g. septic shock) and worse
prognosis. Seventy-eight percent of our patients had septic shock,
which is relatively high in comparison to other studies.6–17 Only
one previous study with a similar design to ours has included a
comparable number of patients with septic shock (77%);16 that
study showed the same overall hospital mortality rate (49%). The
high mortality rate in the present study was not predicted by the
measured APACHE II score on admission;28,30 Khwannimit and
Bhurayanontachai observed this same discrepancy.16 Compared to
other patients with severe sepsis, patients with septic shock
appear to have a worse outcome despite similar severity scores on
ICU admission. The most recent data on the incidence and
mortality of septic shock from France, published by Quenot
et al., show approximately the same results as ours.31
Several authors have reported an increased ICU mortality in
patients who have acquired nosocomial infections; the HAI group
in the present study also had a signiﬁcantly higher mortality rate
compared to the CAI group (65% vs. 37%, p = 0.004). Poor outcomes
among patients with nosocomial infections have been linked to the
higher rates of polymicrobial/multiple sites of infection, higher
APACHE II scores, acute respiratory distress syndrome, and co-
illnesses.14,16,28 However, factors that may have an impact on
outcomes may ﬂuctuate over time: an aging population has been
found to be strongly associated with mortality in some stud-
ies,29,32–34 and a higher rate of multi-resistant microorganisms
may be an explanation for this change over time.27 All of this
conﬂicting information emphasizes the need for new studies.The difference in mortality rate between the two groups in the
present study may therefore be attributable to microbial agents, the
severity of sepsis, and/or underlying disease. The independent
predictors of mortality were a nosocomial origin of infection, a high
APACHE II score, and multidrug-resistant Pseudomonas and fungal
infections, in agreement with several previous studies.16,26–28
However, older age, gender, and septic shock failed to be directly
related to mortality. This may be due to the low number of patients
in this study.
This study has several limitations. First, it was performed in
closed ICUs run by critical care specialists along with medical
residents; these results may therefore not be generalizable to other
hospitals. Second, the aim, by conducting a multivariate analysis,
was to examine determinants of hospital mortality explaining the
difference in outcomes between the HAI and CAI groups. Potential
variables may have been missed. Third, only approximately 10% of
our total ICU admissions were eligible for inclusion. This might be
explained by the relatively liberal admission policy in most of the
study centers, which is understandable in a private practice
context, and/or it may be due to the surgical nature of some of the
units (surgical intensive care) recruiting patients into this cohort.
Indeed recruitment rates were not identical between units. Finally,
as the purpose of the study was to examine hospital outcomes in
infected patients, the 30-day mortality was outside the scope of the
analysis. Thus it would be difﬁcult to pool studies and compare
them due to the heterogeneity of deﬁnitions and of data reported.
In conclusion, severe sepsis and septic shock are a frequent
cause of ICU admission and have a high mortality rate, especially in
HAI patients. A nosocomial origin of infection, the admission
APACHE II score, and multidrug-resistant Pseudomonas and fungal
infections were found to be independent risk factors for hospital
mortality. Special attention should be given to the quality of care
for these patients by applying early guidelines for management
that include appropriate antibiotic recommendations, taking into
consideration the high rate of multidrug-resistant Gram-negative
bacteria.
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